Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

YANELY MD PINEIRO PUEBLA

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1750702189
CMS profile
1311571
Location
PEMBROKE PINES, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$140.17

4 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $140.17 4

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Janssen Pharmaceuticals, Inc $93.75 1
PFIZER INC. $35.18 2
Genentech USA, Inc. $11.24 1

Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

YANELY MD PINEIRO PUEBLA

NPI 1750702189 · CMS profile ID 1311571

Allopathic & Osteopathic Physicians / Internal Medicine

PEMBROKE PINES, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1750702189?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
YANELY MD PINEIRO PUEBLA, NPI 1750702189, CMS profile ID 1311571. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1750702189?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). YANELY MD PINEIRO PUEBLA, NPI 1750702189, CMS profile ID 1311571. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1750702189?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
YANELY MD PINEIRO PUEBLA, NPI 1750702189, CMS profile ID 1311571, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1750702189?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

4 matching records · $140.17 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 4 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–4 of 4.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Genentech USA, Inc. $11.2412/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 708853567 CMS
PFIZER INC. $21.7606/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672222413 CMS
Janssen Pharmaceuticals, Inc $93.7504/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659198283 CMS
PFIZER INC. $13.4202/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671932439 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $140.17 4
PY2021 $93.97 2
PY2022 $220.06 6
PY2023 $390.09 9
PY2024 $285.52 13
PY2025 $127.77 6

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $3,200.00 1
PY2025 Principal investigator $2,476,931.44 112
PY2024 Recipient $3,200.00 1
PY2024 Principal investigator $3,839,557.03 72
PY2023 Principal investigator $3,154,711.62 75
PY2022 Principal investigator $2,403,759.48 31
PY2021 Principal investigator $506,403.80 19

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

75 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $9,930.01 12/31/2023 Non-covered Recipient Entity
Angels Clinical Research Institute
A Phase 3, Randomized, Placebo-Controlled, Double Blind Clinical Study to Evaluate the Efficacy and Safety of MK-4482 in Non-Hospitalized Adults with COVID-19 at High Risk for Disease Progression No dispute reported 06/30/2026 1042524983
Principal investigator 1 PFIZER INC. $2,039.04 12/30/2023 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046130927
Principal investigator 1 PFIZER INC. $18,364.20 12/22/2023 Non-covered Recipient Entity
Angels Clinical Research Institute
A PHASE 2B DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED PARALLEL GROUP DOSE RANGING STUDY TO EVALUATE VIROLOGICAL RESPONSE AND SAFETY OF ORAL PF07817883 IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 No dispute reported 06/30/2026 1046171331
Principal investigator 1 PFIZER INC. $296,672.29 12/14/2023 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046177883
Principal investigator 1 PFIZER INC. $587.00 12/11/2023 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046142941
Principal investigator 1 PFIZER INC. $37.60 12/09/2023 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1045929347
Principal investigator 1 PFIZER INC. $6,889.05 12/08/2023 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1045890939
Principal investigator 1 PFIZER INC. $11,724.48 12/06/2023 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046148317
Principal investigator 1 PFIZER INC. $509.76 11/29/2023 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046246356
Principal investigator 1 PFIZER INC. $403.92 11/27/2023 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1045954165
Principal investigator 1 PFIZER INC. $5,000.00 11/17/2023 Non-covered Recipient Entity
Angels Clinical Research Institute
A PHASE 2B DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED PARALLEL GROUP DOSE RANGING STUDY TO EVALUATE VIROLOGICAL RESPONSE AND SAFETY OF ORAL PF07817883 IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 No dispute reported 06/30/2026 1046276146
Principal investigator 1 PFIZER INC. $1,174.50 11/15/2023 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046267015
Principal investigator 1 PFIZER INC. $13,225.00 10/25/2023 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046087273
Principal investigator 1 PFIZER INC. $7,533.81 10/18/2023 Non-covered Recipient Entity
Angels Clinical Research Institute
A PHASE 2B DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED PARALLEL GROUP DOSE RANGING STUDY TO EVALUATE VIROLOGICAL RESPONSE AND SAFETY OF ORAL PF07817883 IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 No dispute reported 06/30/2026 1046053137
Principal investigator 1 PFIZER INC. $108,399.89 10/12/2023 Non-covered Recipient Entity
Angels Clinical Research Institute
A PHASE 2B DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED PARALLEL GROUP DOSE RANGING STUDY TO EVALUATE VIROLOGICAL RESPONSE AND SAFETY OF ORAL PF07817883 IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 No dispute reported 06/30/2026 1046114617
Principal investigator 1 Amgen Inc. $4,724.16 09/25/2023 Non-covered Recipient Entity
ANGELS CLINICAL RESEARCH INSTITUTE
P3 AD Adolescent Mono No dispute reported 06/30/2026 1029653437
Principal investigator 1 PFIZER INC. $45,528.08 09/23/2023 Non-covered Recipient Entity
Angels Clinical Research Institute
A PHASE 2B DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED PARALLEL GROUP DOSE RANGING STUDY TO EVALUATE VIROLOGICAL RESPONSE AND SAFETY OF ORAL PF07817883 IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 No dispute reported 06/30/2026 1046130913
Principal investigator 1 PFIZER INC. $9,180.00 09/20/2023 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046017675
Principal investigator 1 PFIZER INC. $122,453.25 09/15/2023 Non-covered Recipient Entity
Angels Clinical Research Institute
A PHASE 2B DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED PARALLEL GROUP DOSE RANGING STUDY TO EVALUATE VIROLOGICAL RESPONSE AND SAFETY OF ORAL PF07817883 IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 No dispute reported 06/30/2026 1046237715
Principal investigator 1 PFIZER INC. $16,741.60 09/14/2023 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046243197
Principal investigator 1 PFIZER INC. $69,246.90 09/13/2023 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1045927135
Principal investigator 1 PFIZER INC. $91,684.15 09/07/2023 Non-covered Recipient Entity
Angels Clinical Research Institute
A PHASE 2B DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED PARALLEL GROUP DOSE RANGING STUDY TO EVALUATE VIROLOGICAL RESPONSE AND SAFETY OF ORAL PF07817883 IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 No dispute reported 06/30/2026 1046253511
Principal investigator 1 PFIZER INC. $60,100.00 09/02/2023 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1045975997
Principal investigator 1 PFIZER INC. $403.92 08/31/2023 Non-covered Recipient Entity
Palm Springs Community
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046257555
Principal investigator 1 PFIZER INC. $2,305.26 08/30/2023 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1045919989
Principal investigator 1 PFIZER INC. $6,257.25 08/29/2023 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1045939157
Principal investigator 1 PFIZER INC. $15,252.48 08/26/2023 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1045993867
Principal investigator 1 PFIZER INC. $80,875.97 08/24/2023 Non-covered Recipient Entity
Angels Clinical Research Institute
A PHASE 2B DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED PARALLEL GROUP DOSE RANGING STUDY TO EVALUATE VIROLOGICAL RESPONSE AND SAFETY OF ORAL PF07817883 IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 No dispute reported 06/30/2026 1046149595
Principal investigator 1 PFIZER INC. $442.26 08/23/2023 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1045919975
Principal investigator 1 PFIZER INC. $1,105.65 08/16/2023 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046227715
Principal investigator 1 PFIZER INC. $33,071.77 08/11/2023 Non-covered Recipient Entity
Angels Clinical Research Institute
A PHASE 2B DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED PARALLEL GROUP DOSE RANGING STUDY TO EVALUATE VIROLOGICAL RESPONSE AND SAFETY OF ORAL PF07817883 IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 No dispute reported 06/30/2026 1045898593
Principal investigator 1 PFIZER INC. $15,117.30 08/09/2023 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046117233
Principal investigator 1 PFIZER INC. $22,840.66 08/08/2023 Non-covered Recipient Entity
Angels Clinical Research Institute
A PHASE 2B DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED PARALLEL GROUP DOSE RANGING STUDY TO EVALUATE VIROLOGICAL RESPONSE AND SAFETY OF ORAL PF07817883 IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 No dispute reported 06/30/2026 1046088531
Principal investigator 1 PFIZER INC. $35,028.33 08/05/2023 Non-covered Recipient Entity
Angels Clinical Research Institute
A PHASE 2B DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED PARALLEL GROUP DOSE RANGING STUDY TO EVALUATE VIROLOGICAL RESPONSE AND SAFETY OF ORAL PF07817883 IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 No dispute reported 06/30/2026 1046059757
Principal investigator 1 PFIZER INC. $8,812.80 08/02/2023 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1045926555
Principal investigator 1 PFIZER INC. $17,541.90 07/26/2023 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046107985
Principal investigator 1 PFIZER INC. $21,720.42 07/19/2023 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046280221
Principal investigator 1 PFIZER INC. $631,952.69 07/18/2023 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046017661
Principal investigator 1 PFIZER INC. $42,167.52 07/06/2023 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046097965
Principal investigator 1 PFIZER INC. $417.15 06/30/2023 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046318899
Principal investigator 1 PFIZER INC. $20,518.65 06/29/2023 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046054387
Principal investigator 1 PFIZER INC. $1,190.70 06/22/2023 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046005553
Principal investigator 1 PFIZER INC. $20,730.87 06/16/2023 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046047263
Principal investigator 1 ABBVIE INC. $6,772.50 06/15/2023 Non-covered Recipient Entity
ANGELS CLINICAL RESEARCH INSTITUTE
Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB) No dispute reported 06/30/2026 998386973
Principal investigator 1 PFIZER INC. $680.40 06/14/2023 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046030357
Principal investigator 1 PFIZER INC. $1,490.40 06/07/2023 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046070607
Principal investigator 1 PFIZER INC. $337,101.44 06/03/2023 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1045987777
Principal investigator 1 PFIZER INC. $6,293.70 05/25/2023 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1045921191
Principal investigator 1 PFIZER INC. $587.00 05/24/2023 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046005567
Principal investigator 1 PFIZER INC. $6,974.10 05/16/2023 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046360091
Principal investigator 1 PFIZER INC. $3,402.00 05/10/2023 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046310035
Principal investigator 1 PFIZER INC. $115,739.55 05/09/2023 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046017159
Principal investigator 1 PFIZER INC. $194.12 05/03/2023 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046315055
Principal investigator 1 PFIZER INC. $118,640.70 04/27/2023 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046291195
Principal investigator 1 PFIZER INC. $27,270.00 04/12/2023 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046009871
Principal investigator 1 PFIZER INC. $21,129.67 04/12/2023 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046128227
Principal investigator 1 PFIZER INC. $46,203.00 04/05/2023 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046302273
Principal investigator 1 PFIZER INC. $24,260.88 03/25/2023 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046045027
Principal investigator 1 PFIZER INC. $40,665.89 03/18/2023 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046124065
Principal investigator 1 PFIZER INC. $792.88 03/10/2023 Non-covered Recipient Entity
Palm Springs Community
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046058181
Principal investigator 1 PFIZER INC. $12,927.60 03/09/2023 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046292951
Principal investigator 1 PFIZER INC. $5,057.90 03/07/2023 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1045945645
Principal investigator 1 PFIZER INC. $45,586.80 02/28/2023 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046030955
Principal investigator 1 PFIZER INC. $56,392.47 02/18/2023 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046289717
Principal investigator 1 PFIZER INC. $57,981.69 02/17/2023 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046129429
Principal investigator 1 PFIZER INC. $678.40 02/17/2023 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046259475
Principal investigator 1 PFIZER INC. $1,864.89 02/10/2023 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046292891
Principal investigator 1 PFIZER INC. $123,444.00 02/07/2023 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1045945659
Principal investigator 1 PFIZER INC. $189.80 02/01/2023 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1045974379
Principal investigator 1 PFIZER INC. $339.20 01/31/2023 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046033765
Principal investigator 1 PFIZER INC. $949.00 01/25/2023 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046009857
Principal investigator 1 PFIZER INC. $678.40 01/18/2023 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046090019
Principal investigator 1 PFIZER INC. $170,982.80 01/12/2023 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046026865
Principal investigator 1 PFIZER INC. $38,399.40 01/11/2023 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046123475
Principal investigator 1 PFIZER INC. $1,138.80 01/09/2023 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046340475